glp 1 and pancreatic cancer Glucagon-like peptide-1 receptor agonists risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials Glucagon-like peptide-1 (GLP-1) action on
Description
It's not a weight loss supplement
Weekly semaglutide at 2.4 mg can achieve weight reductions of 10%12%, while tirzepatide has even demonstrated marked improvement in specific trials, reaching 5%20%+ ( More importantly, cardiovascular and renal outcome studies have demonstrated that GLP-1RAs and related multi-receptor agonists not only lower body weight and blood glucose but also significantly reduce the risk of major adverse cardiovascular events (MACE) and the worsening of renal function
Eur J Clin Invest 22: 283-291, 1992
the average is 7-14 days
